GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroMetrix Inc (NAS:NURO) » Definitions » Piotroski F-Score

NURO (NeuroMetrix) Piotroski F-Score : 2 (As of Dec. 15, 2024)


View and export this data going back to 2004. Start your Free Trial

What is NeuroMetrix Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NeuroMetrix has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for NeuroMetrix's Piotroski F-Score or its related term are showing as below:

NURO' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 7
Current: 2

During the past 13 years, the highest Piotroski F-Score of NeuroMetrix was 7. The lowest was 1. And the median was 3.


NeuroMetrix Piotroski F-Score Historical Data

The historical data trend for NeuroMetrix's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroMetrix Piotroski F-Score Chart

NeuroMetrix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 5.00 5.00 3.00 2.00

NeuroMetrix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 2.00 2.00 2.00

Competitive Comparison of NeuroMetrix's Piotroski F-Score

For the Medical Devices subindustry, NeuroMetrix's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroMetrix's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroMetrix's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where NeuroMetrix's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was -1.65 + -3.03 + -1.488 + -1.508 = $-7.68 Mil.
Cash Flow from Operations was -1.451 + -2.081 + -1.364 + -1.792 = $-6.69 Mil.
Revenue was 1.318 + 1.094 + 0.769 + 0.587 = $3.77 Mil.
Gross Profit was 0.848 + 0.517 + 0.492 + 0.312 = $2.17 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(21.287 + 21.424 + 20.664 + 18.93 + 17.189) / 5 = $19.8988 Mil.
Total Assets at the begining of this year (Sep23) was $21.29 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $16.80 Mil.
Total Current Liabilities was $1.21 Mil.
Net Income was -0.692 + -1.574 + -1.537 + -1.769 = $-5.57 Mil.

Revenue was 1.847 + 1.725 + 1.656 + 1.203 = $6.43 Mil.
Gross Profit was 1.23 + 1.198 + 1.119 + 0.782 = $4.33 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(24.032 + 24.67 + 23.61 + 22.774 + 21.287) / 5 = $23.2746 Mil.
Total Assets at the begining of last year (Sep22) was $24.03 Mil.
Long-Term Debt & Capital Lease Obligation was $0.12 Mil.
Total Current Assets was $20.71 Mil.
Total Current Liabilities was $1.26 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NeuroMetrix's current Net Income (TTM) was -7.68. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NeuroMetrix's current Cash Flow from Operations (TTM) was -6.69. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=-7.676/21.287
=-0.36059567

ROA (Last Year)=Net Income/Total Assets (Sep22)
=-5.572/24.032
=-0.23185752

NeuroMetrix's return on assets of this year was -0.36059567. NeuroMetrix's return on assets of last year was -0.23185752. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

NeuroMetrix's current Net Income (TTM) was -7.68. NeuroMetrix's current Cash Flow from Operations (TTM) was -6.69. ==> -6.69 > -7.68 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=0/19.8988
=0

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=0.123/23.2746
=0.00528473

NeuroMetrix's gearing of this year was 0. NeuroMetrix's gearing of last year was 0.00528473. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=16.796/1.21
=13.88099174

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=20.706/1.26
=16.43333333

NeuroMetrix's current ratio of this year was 13.88099174. NeuroMetrix's current ratio of last year was 16.43333333. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

NeuroMetrix's number of shares in issue this year was 2.033. NeuroMetrix's number of shares in issue last year was 1.065. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2.169/3.768
=0.57563694

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4.329/6.431
=0.6731457

NeuroMetrix's gross margin of this year was 0.57563694. NeuroMetrix's gross margin of last year was 0.6731457. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=3.768/21.287
=0.17700944

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=6.431/24.032
=0.26760153

NeuroMetrix's asset turnover of this year was 0.17700944. NeuroMetrix's asset turnover of last year was 0.26760153. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NeuroMetrix has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

NeuroMetrix  (NAS:NURO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


NeuroMetrix Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of NeuroMetrix's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroMetrix Business Description

Traded in Other Exchanges
N/A
Address
4B Gill Street, Woburn, MA, USA, 01801
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
Executives
Bradley M Fluegel director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Thomas T Higgins officer: Chief Financial Officer
Topline Capital Management, Llc other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Topline Capital Partners, Lp 10 percent owner 544 EUCLID STREET, SANTA MONICA CA 90402
Mcbirney Collin other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Shai Gozani director, officer: Chairman, President and CEO C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Francis X Mcgillin officer: Senior VP, Consumer C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Avermaete David Van director C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Krishnamurthy Balachandran officer: S. VP and GM, International C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Nancy E Katz director CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
Neurometrix Inc officer: Senior Vice President & GM
Walter Christensen officer: Sr. VP, Global Sales C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Timothy R Surgenor director 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035
Deerfield Management Company, L.p. (series C) 10 percent owner 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

NeuroMetrix Headlines

From GuruFocus

Q2 2024 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus News 10-09-2024

Q1 2021 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q3 2021 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q1 2022 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

NeuroMetrix Reports Q1 2024 Business Highlights

By Marketwired 05-15-2024

Q4 2022 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q4 2023 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-28-2024

Q4 2021 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q1 2023 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024